DESTINY-Breast03 Phase 3 Study Results
DESTINY-Breast03 Study Design
Patients with HER2+ mBCa
treated with trastuzumab
and/or taxane
R
1:1
Received T-DXd
5.4 mg/kg Q3W
n = 257b
Received T-DM1
3.6 mg/kg Q3WC
n = 261b
10
Daiichi-Sankyo
DESTINY-Breast03
Primary data cutoff: May 21, 2021
Median treatment duration1:
T-DXd: 14.3 months
T-DM1: 6.9 months
Safety update: Sept 7, 2021
Median treatment duration:
T-DXd: 16.1 months
T-DM1: 6.9 months
Prespecified analysis of TEAEs
Selected TEAES (ILD/pneumonitis,
nausea, vomiting, fatigue, alopecia,
hematologic events), including
EAIRS
Objective of the study was to provide updated safety data with additional analyses in patients with
HER2+ MBC treated with T-DXd or T-DM1 in DESTINY-Breast03
EAIRS, exposure-adjusted incidence rates; HER2, human epidermal growth factor receptor 2; ILD, interstitial lung disease; mBC, metastatic breast cancer; Q3W, every 3 weeks; T-DM1, trastuzumab emtansine; T-DXd, trastuzumab deruxtecan;
TEAE, treatment-emergent adverse event.
aCentral testing of archived sample for HER2 status. "Number of treated patients (not the randomized number of patients). Or in accordance with the local label.
1. Cortés J et al. N Engl J Med. 2022;386:1143-1154.
ASCO 2022 #1000 Oral
25View entire presentation